United Therapeutics EVP & General Counsel Executes 10b5-1 Option Exercise and Sale

Executive Summary

On October 15, 2026, Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp ($UTHR), exercised stock options for 8,300 shares at an exercise price of $146.03 per share and subsequently sold all 8,300 acquired shares across six open-market tranches at weighted average prices between $541.64 and $546.56 per share, generating aggregate gross proceeds of approximately $4.52 million.

Transaction Details

• Nature of Trade: The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025.
• Derivative Exercise: 8,300 stock options exercised at $146.03 per share (options expiring March 15, 2027).
• Open Market Sales: 8,300 shares sold at a weighted average price of ~$544.30 per share.
• Net Equity Impact: The insider's direct common stock position remains unchanged at 45,172 shares, while remaining derivative option holdings stand at 30,940.

Market & Significance Assessment

• Trading Significance: Low. The transactions represent a scheduled cashless option exercise and sale under an established Rule 10b5-1 plan without any reduction in the insider's base direct shareholding.